Catalyst Pharmaceuticals, Inc.

NasdaqCM:CPRX Stock Report

Market Cap: US$2.6b

Catalyst Pharmaceuticals Management

Management criteria checks 4/4

Catalyst Pharmaceuticals' CEO is Rich Daly, appointed in Jan 2024, has a tenure of 1.75 years. total yearly compensation is $7.77M, comprised of 9.6% salary and 90.4% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $4.73M. The average tenure of the management team and the board of directors is 3.4 years and 10.7 years respectively.

Key information

Rich Daly

Chief executive officer

US$7.8m

Total compensation

CEO salary percentage9.65%
CEO tenure1.8yrs
CEO ownership0.2%
Management average tenure3.4yrs
Board average tenure10.7yrs

Recent management updates

Recent updates

Does Catalyst Pharmaceuticals (NASDAQ:CPRX) Deserve A Spot On Your Watchlist?

Sep 26
Does Catalyst Pharmaceuticals (NASDAQ:CPRX) Deserve A Spot On Your Watchlist?

Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma

May 31

Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings Are Not Doing Enough For Some Investors

May 30
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings Are Not Doing Enough For Some Investors

Cautious Investors Not Rewarding Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Performance Completely

Feb 21
Cautious Investors Not Rewarding Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Performance Completely

We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease

Dec 19
We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve

Nov 13
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve

Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings

Nov 07
Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings
User avatar

Successful Product Expansions And Global Partnerships Fuel Revenue Surge And Profit Growth

Diversification and expansion strategies, including new product launches and international partnerships, contribute to financial stability and potential global revenue growth.

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24
Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29
Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06
With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27
Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

CEO Compensation Analysis

How has Rich Daly's remuneration changed compared to Catalyst Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

US$209m

Mar 31 2025n/an/a

US$197m

Dec 31 2024US$8mUS$750k

US$164m

Sep 30 2024n/an/a

US$143m

Jun 30 2024n/an/a

US$68m

Mar 31 2024n/an/a

US$65m

Dec 31 2023US$14mn/a

US$71m

Sep 30 2023n/an/a

US$62m

Jun 30 2023n/an/a

US$116m

Mar 31 2023n/an/a

US$99m

Dec 31 2022US$390kn/a

US$83m

Sep 30 2022n/an/a

US$67m

Jun 30 2022n/an/a

US$54m

Mar 31 2022n/an/a

US$45m

Dec 31 2021US$132kn/a

US$39m

Sep 30 2021n/an/a

US$42m

Jun 30 2021n/an/a

US$75m

Mar 31 2021n/an/a

US$72m

Dec 31 2020US$115kn/a

US$75m

Sep 30 2020n/an/a

US$71m

Jun 30 2020n/an/a

US$42m

Mar 31 2020n/an/a

US$43m

Dec 31 2019US$142kn/a

US$32m

Sep 30 2019n/an/a

US$9m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$29m

Dec 31 2018US$211kn/a

-US$34m

Compensation vs Market: Rich's total compensation ($USD7.77M) is about average for companies of similar size in the US market ($USD7.10M).

Compensation vs Earnings: Rich's compensation has been consistent with company performance over the past year.

CEO

Rich Daly (64 yo)

1.8yrs
Tenure
US$7,774,160
Compensation

Mr. Richard John Daly, also known as Rich, MBA, He serves as President at Catalyst Pharmaceuticals, Inc since January 1, 2024. He had been an Independent Director at Catalyst Pharmaceuticals, Inc. from Feb...

Leadership Team

NamePositionTenureCompensationOwnership
Richard John Daly
President1.8yrsUS$7.77m0.19%
$ 4.7m
Michael Kalb
Executive VP1.8yrsUS$6.18m0.0034%
$ 87.5k
Steven Miller
Executive VP16yrsUS$3.55m0.87%
$ 22.1m
Jeffrey Del Carmen
Executive VP & Chief Commercial Officer5.3yrsUS$2.64m0%
$ 0
Preethi Sundaram
Chief Strategy Officer4.3yrsUS$2.53m0.034%
$ 856.2k
Mary Coleman
VP & Head of Investor Relations4.2yrsno datano data
Brian Elsbernd
Chief Compliance Officer & Chief Legal Officer9.7yrsUS$353.27k0.22%
$ 5.6m
Gregg Russo
Chief Human Resources Officerless than a yearno datano data
Stanley Iyadurai
Senior Vice President of Medical Affairs & Drug Discovery2.6yrsno datano data
William Andrews
Chief Medical Officerless than a yearno datano data
Philip Schwartz
Corporate Secretaryno datano datano data
3.4yrs
Average Tenure
60.5yo
Average Age

Experienced Management: CPRX's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard John Daly
President10.7yrsUS$7.77m0.19%
$ 4.7m
David Tierney
Independent Director23yrsUS$381.02k0.31%
$ 7.9m
Patrick McEnany
Co-Founder & Non-Executive Chairman23.8yrsUS$844.76k3.5%
$ 89.2m
Donald Denkhaus
Independent Director10.7yrsUS$386.27k0.40%
$ 10.3m
Eugene Laska
Member of Scientific Advisory Boardno datano datano data
Robert Fechtner
Member of Scientific Advisory Boardno datano datano data
Jonathan Brodie
Chairman of Scientific Advisory Boardno datano datano data
Molly Harper
Lead Independent Director4.3yrsUS$439.14k0.0055%
$ 140.5k
Richard Silverman
Member of Scientific Advisory Board14.9yrsno datano data
Daniel Curran
Directorless than a yearno datano data
Tamar Thompson
Independent Director2.4yrsUS$381.02k0.0011%
$ 29.3k
10.7yrs
Average Tenure
61yo
Average Age

Experienced Board: CPRX's board of directors are seasoned and experienced ( 10.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/05 00:39
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Catalyst Pharmaceuticals, Inc. is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luke HerrmannBaird
null nullBaird
Joel BeattyBaird